Racing against COVID-19- a vaccines strategy for Europe
Reinhilde Veugelers () and
Georg Zachmann ()
Policy Contributions from Bruegel
The fast development of vaccines is an essential part of the long-term solution to COVID-19, but vaccine development has high costs and carries the risk of high failure rates. There are currently too few promising projects in the clinical trial pipeline to guarantee at least one vaccine soon. More projects need to pass through the development pipeline in parallel. Vaccines should ultimately be widely available to all who need them...
New Economics Papers: this item is included in nep-ppm
References: Add references at CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:bre:polcon:36267
Access Statistics for this paper
More papers in Policy Contributions from Bruegel Contact information at EDIRC.
Bibliographic data for series maintained by Bruegel ().